Related references
Note: Only part of the references are listed.Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Incidence and Clinical Significance of Immunogenicity to Infliximab in Crohn's Disease: A Critical Systematic Review
Andrea Cassinotti et al.
INFLAMMATORY BOWEL DISEASES (2009)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Long-term durability of Crohn's disease treatment with infliximab
Stephen J. Rudolph et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
M. Svenson et al.
RHEUMATOLOGY (2007)
Infliximab dose intensification in Crohn's disease
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2007)
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis
C. J. van der Laken et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis
C Aybay et al.
RHEUMATOLOGY INTERNATIONAL (2006)
Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease
S Candon et al.
CLINICAL IMMUNOLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
RJ Farrell et al.
GASTROENTEROLOGY (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration
SL Brown et al.
ARTHRITIS AND RHEUMATISM (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs
C Hennig et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)
A simple classification of Crohn's disease: Report of the Working Party for the world congresses of gastroenterology, Vienna 1998
C Gasche et al.
INFLAMMATORY BOWEL DISEASES (2000)